Jane Street’s Denali Therapeutics DNLI Stock Holding History

Jane Street’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$365K	Buy	+19,000	New	+$378K	﹤0.01%	8787
2024 Q4	–	Sell	-18,700	Closed	-$545K	–	9624
2024 Q3	$545K	Buy	+18,700	New	+$464K	﹤0.01%	7036
2023 Q2	–	Sell	-55,900	Closed	-$1.29M	–	8839
2023 Q1	$1.29M	Buy	+55,900	New	+$1.54M	﹤0.01%	4554
2022 Q1	–	Sell	-24,500	Closed	-$1.09M	–	10423
2021 Q4	$1.09M	Buy	+24,500	New	+$1.16M	﹤0.01%	5712

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's DNLI Position: Q1 2026 in Review

Jane Street reduced its Denali Therapeutics (DNLI) stake by 25% in Q1 2026, selling an estimated $214K and leaving 32,147 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #7548.

Jane Street first reported a position in DNLI in Q3 2018 and has held it in 25 quarters since. The position peaked at $10.8M in Q3 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Jane Street held 32,147 shares of Denali Therapeutics worth $617K as of Q1 2026.
Jane Street sold 10,775 Denali Therapeutics shares in Q1 2026, an estimated $214K.
Denali Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7548 holding.
Jane Street first reported a position in Denali Therapeutics in Q3 2018 and has held it in 25 quarters since.
Jane Street's Denali Therapeutics position peaked at $10.8M in Q3 2024.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.